Helsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR

Lugano, Switzerland – Shanghai, China, October 12, 2021 -...

Helsinn Group announces oral presentation of data at AACR-NCI- EORTC relating to a potent and highly selective investigational RET inhibitor

Lugano, Switzerland, 7 October 2021 – Helsinn Group, a Swiss...

È ora disponibile l’edizione 2021 della pubblicazione di KPMG “Site Selection for Life Sciences Companies in Europe”

Trovare la giusta ubicazione per le aziende attive nel...